[Explanation] On June 1, the inaugural meeting of the Guangdong Provincial Clinical Research Quality Control Center was held in Guangzhou.
Zhong Nanshan, an academician of the Chinese Academy of Engineering, said in his speech that the quality control of clinical research is the "lifeline", and high-level clinical research quality control is very important for scientific and technological innovation in the medical field.
[Concurrent] Zhong Nanshan, academician of the Chinese Academy of Engineering and consultant expert of the Guangdong Provincial Clinical Research Quality Control Center
In fact, we know that when we talk about innovation now, "only innovators win" and "only innovators are strong".
So often a lot of innovation, or what we call the so-called innovation, could have been better, (but) our quality control is not good enough, so there will be flaws and problems, this is actually a "lifeline" ".
We clinicians often like to have experience, and at the same time, it is proved by my experience that it is effective, so it is effective, this is not enough.
So today I feel that in terms of clinical practice, the improvement of clinical quality is the way we must take, and it is the way we must follow.
[Explanation] Zhong Nanshan said that our traditional Chinese medicine has made great achievements in the past three years, and many medicines have also obtained new evidence through evidence-based medicine.
Whether it is traditional Chinese medicine or Western medicine, there should be a strict quality control of clinical research.
[Concurrent] Zhong Nanshan, academician of the Chinese Academy of Engineering and consultant expert of the Guangdong Provincial Clinical Research Quality Control Center
Whether it is Chinese medicine, Western medicine, Chinese medicine, or Western medicine, there should be a strict quality observation.
Only in this way will our Chinese medicine and Western medicine move forward steadily.
This is an RCT (randomized controlled trial) that we often talk about. At the same time, we must pay special attention to real-world research, because real-world research can confirm whether RCT is right or not and whether it can be expanded to the whole population.
[Explanation] Zhong Nanshan said that today, China is no less than Western countries in terms of vaccine production capacity.
Now there are real-world data from many countries that the "three-injection" inactivated vaccine is as effective as the mRNA vaccine in preventing severe illness.
[Concurrent] Zhong Nanshan, academician of the Chinese Academy of Engineering and consultant expert of the Guangdong Provincial Clinical Research Quality Control Center
China is no less than Western countries in vaccine production later, why?
We originally had relatively good experience and foundation for inactivated vaccines.
(During the epidemic) this (R&D) process is a bit different from the previous step-by-step process, it overlaps a bit.
But we still follow the method of evidence-based medicine and go down step by step, so it has been proved that it is still effective.
The "three-needle" inactivated vaccine is as effective as the mRNA vaccine for severe cases.
So this requires a lot of high-quality observations, so this is all inseparable from strict quality control.
[Explanation] According to reports, the Guangdong Provincial Clinical Research Quality Control Center is mainly responsible for technical verification, monitoring and evaluation, consulting analysis, professional training and technical guidance services for clinical research carried out in the province, and at the same time undertakes the entrustment of the Guangdong Provincial Health and Health Commission and clinical Research other work related to standardized management.
(Reported by reporter He Junjie and Cai Minjie in Guangzhou)
Responsible editor: [Luo Pan]